About

David Fink has more than 40 years of successful new product development experience in the medical device industry ranging from early phase research, strategy and business development through detailed design to commercial launch. His role at Ximedica is working closely with client companies to align their project needs effectively with Ximedica’s extensive development capabilities. Prior experience includes over 20 years at Covidien/Kendall, most recently serving as Director of Research & Development managing multiple development groups in the fields of cardiology, radiology, respiratory care and advanced wound care. Mr Fink’s experience includes 12 years in antimicrobial device platform development.

Contributions

INJECTION

THE CHALLENGES OF A CHANGING MARKET & THE BENEFITS OF DEVELOPMENT FLEXIBILITY

David Fink and Sheila Trgovac describe how adopting a flexible development model in mid-to-late development brings benefits through to commercialisation, especially in the context of a changing market.

More contributions

INJECTION

ASSESSING USABILITY EARLY FOR OPTIMAL INJECTION PEN DESIGN

David Fink and Stefan Gaul use the example of Haselmeier’s D-Flex system to explain why it is important to undertake a full use-related risk analysis for injection pen products to assess their usability and identify any risks, highlighting the importance of considering usability right from the start.